Videos

Pembrolizumab Lowers Distant Recurrence Risk in Resected Merkel Cell Carcinoma

11/10/2025

Janice Mehnert, MD, NYU Langone Health, New York, New York, discusses results from the phase 3 STAMP trial evaluating pembrolizumab versus observation in patients with resected merkel cell carcinoma.

Results demonstrated that adjuvant pembrolizumab led to a meaningful reduction in the risk of distant metastasis and a numerical improvement in relapse-free survival, though not statistically significant at this analysis. These findings suggest pembrolizumab may help delay recurrence and disease spread in this rare, aggressive skin cancer.

These results were presented at the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin, Germany.

Source:

Mehnert JM, Lee SJ, Gastman B, et al. ECOG-ACRIN EA6174: STAMP: Surgically treated adjuvant merkel cell carcinoma with pembrolizumab, a phase III trial. Presented at the 2025 ESMO Congress. October 17-21, 2025; Berlin, Germany. LBA56

© 2025 HMP Global. All Rights Reserved.

Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates.

Recent News

News

Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Rise

01/29/2026

Stephanie Holland

Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...

Results from a real-world...

01/29/2026

Oncology

News

Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer

01/29/2026

Emily Estrada

The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.

The addition of elenagen to...

01/29/2026

Oncology

News

Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma

01/28/2026

Stephanie Holland

Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.

Results from the phase 1/2...

01/28/2026

Oncology

News

Advances in Antibody-Based Therapies for the Treatment of Relapsed Small-Cell Lung Cancer

01/27/2026

Gina Tomaine

Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.

Antibody-based therapies are...

01/27/2026

Oncology

News

Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial

01/27/2026

Emily Estrada

Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.

Tucatinib plus trastuzumab...

01/27/2026

Oncology

News

TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC

01/27/2026

Emily Estrada

A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.

A TOMOX-bevacizumab combination...

01/27/2026

Oncology

News

ISL1 Emerges as a Potential Predictive Biomarker for Efficacy of Lurbinectedin in Relapsed SCLC

01/27/2026

Gina Tomaine

A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.

A translational study identified...

01/27/2026

Oncology

News

CSF-1-Targeted Therapies Continue to Redefine Systemic Treatment for TGCT

01/26/2026

Gina Tomaine

Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.

Systemic CSF-1R inhibition...

01/26/2026

Oncology

News

Sacituzumab Govitecan Plus Pembrolizumab Significantly Prolongs PFS in PD-L1-Positive Triple-Negative Breast Cancer

01/22/2026

Stephanie Holland

Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...

Results from the phase 3...

01/22/2026

Oncology

News

Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer

01/21/2026

Stephanie Holland

Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...

Results from a multicenter,...

01/21/2026

Oncology